Humana (NYSE:HUM) Releases FY 2024 Earnings Guidance

Humana (NYSE:HUM) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 16.000- for the period, compared to the consensus estimate of 16.150. The company issued revenue guidance of -.

Humana Stock Performance

Shares of HUM stock opened at $239.85 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The business has a fifty day moving average of $274.32 and a 200 day moving average of $322.31. The firm has a market capitalization of $28.88 billion, a price-to-earnings ratio of 21.24, a price-to-earnings-growth ratio of 2.15 and a beta of 0.53. Humana has a 1 year low of $213.31 and a 1 year high of $475.00.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.68. The firm had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, research analysts expect that Humana will post 16.14 earnings per share for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.48%. The ex-dividend date is Tuesday, December 31st. Humana’s dividend payout ratio (DPR) is currently 31.36%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on HUM shares. Oppenheimer lowered their price target on shares of Humana from $400.00 to $280.00 and set an “outperform” rating on the stock in a report on Thursday, October 3rd. Truist Financial lowered their target price on Humana from $400.00 to $260.00 and set a “hold” rating on the stock in a research note on Friday, October 11th. Barclays raised their target price on Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Leerink Partnrs downgraded Humana from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Jefferies Financial Group cut shares of Humana from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $519.00 to $253.00 in a research note on Monday, October 7th. Twenty equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $300.50.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.